Semaglutide 2.4 mg: the latest GLP-1RA approved for obesity

R Villela, R Correa - Journal of Investigative Medicine, 2022 - journals.sagepub.com
Overweight and obesity are one of the most relevant health factors; according to the WHO,
39% of people globally are overweight and 13% obese. 1 Body weight loss of 3%–5% has …
被引用次数：9 相关文章

[引用][C] Semaglutide 2.4 mg: the latest GLP-1RA approved for obesity.

R Villela, R Correa - Journal of Investigative Medicine: the Official …, 2022 - europepmc.org
Semaglutide 2.4 mg: the latest GLP-1RA approved for obesity. - Abstract - Europe PMC Sign in
| Create an account https://orcid.org Europe PMC Menu About Tools Developers Help Contact …

[引用][C] Semaglutide 2.4 mg: the latest GLP-1RA approved for obesity

R Villela, R Correa - Journal of investigative medicine …, 2022 - pubmed.ncbi.nlm.nih.gov
Semaglutide 2.4 mg: the latest GLP-1RA approved for obesity Semaglutide 2.4 mg: the latest
GLP-1RA approved for obesity J Investig Med. 2022 Jan;70(1):3-4. doi: 10.1136/jim-2021-002227 …

Semaglutide 2.4 mg: the latest GLP-1RA approved for obesity

R Villela, R Correa - Journal of Investigative Medicine, 2022 - search.proquest.com
Abstract Correspondence to Dr Ricardo Correa, Department of Medicine, The University of
Arizona College of Medicine Phoenix and Phoenix VAMC, Phoenix, AZ 85022, USA; …